ROCKVILLE, Md., Nov. 5, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX ) today announced that on Tuesday, November 12, 2013, the Company will release its financial results for the third quarter ended September 30, 2013. The Company's management team will host a conference call discussing the Company's financial results and recent developments on Tuesday, November 12, 2013 at 4:30 pm (EST). The call can be accessed by dialing 1-877-303-6253 (domestic) or 1-973-409-9610 (international) five minutes prior to the start of the call and providing the passcode 97246097.
The recorded, listen-only webcast of the conference call can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.macrogenics.com . A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company's website for two weeks following the call.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. www.macrogenics.com
Jim Karrels, Vice President, CFO MacroGenics, Inc. 1-301-251-5172, Karen Sharma, Director MacDougall Biomedical Communications 1-781-235-3060,
